Neuronal Signaling

Items 451-500 of 576

per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. tranquilizer

    Uldazepam is a benzodiazepine derivative and can be used to treat patients with anxiety syndromes as tranquilizer.
  2. calmodulin inhibitor

    Metofenazate is a selective calmodulin inhibitor.
  3. PSD95-nNOS interactions inhibitor

    IC87201, an inhibitor of PSD95-nNOS protein-protein interactions, suppresses NMDAR-dependent NO and cGMP formation.
  4. nNOS/PSD-95 interaction inhibitor

    ZL006 is a potent inhibitor of nNOS/PSD-95 interaction, and inhibits NMDA receptor-mediated NO synthesis.
  5. platelet inhibitor

    TAK-024 is a platelet inhibitor with IC50s of 31, 79 and 51 nM in human, monkey and guinea pig, respectively.
  6. benzodiazepine receptor antagonist

    Sarmazenil is a benzodiazepine receptor antagonist.
  7. GABA transaminase inhibitor

    L-DABA (L-2,4-Diaminobutyric acid) is a week GABA transaminase inhibitor with an IC50 of larger than 500 μM; exhibits antitumor activity in vivo and in vitro.
  8. 4-Acetamidobutanoic acid (N-acetyl GABA) is a γ-aminobutyric acid (GABA) derivative.
  9. DL-AP5 is the racemic version of the selective N-methyl-D-aspartate (NMDA) receptor antagonist.
  10. hM3Dq agonist.

    DREADD agonist 21 is a potent human muscarinic acetylcholine M3 receptors (hM3Dq) agonist(EC50=1.7 nM).
  11. GABA receptor agonist

    Isoguvacine hydrochloride is a GABA receptor agonist.
  12. NMDA receptor agonist

    Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction.
  13. RAGE inhibitor

    Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer??s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB).
  14. GlyT1 inhibitor

    Tilapertin is an oral inhibitor of glycine transporter type-1 (GlyT1).
  15. GABAA(α2/3) receptor modulator

    AZD-6280 is a selective GABAA(α2/3) receptor modulator, used for treatment of generalized anxiety disorder.
  16. CaMKII inhibitor

    Rimacalib is a Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor, with IC50s of ~1 μM for CaMKIIα to ~30 μM for CaMKIIγ.
  17. COX2 inhibitor

    Thioflosulide (L-745337) is a selective cyclooxygenase-2 (COX2) inhibitor, with an IC50 of 2.3 nM, and shows anti-inflammatory activity.
  18. COX-2/5-LO inhibitor

    S-2474 is an inhibitor of COX-2 and 5-lipoxygenase (5-LO), with IC50s of 11 nM and 27 μM for COX-2 and COX-1 in human intact cells, and used as a nonsteroidal anti-inflammatory drug.
  19. NMDA receptor antagonist

    Perzinfotel (EAA-090) is a potent, selective, and competitive NMDA receptor antagonist with neuroprotective effects. Perzinfotel (EAA-090) shows high affinity (IC50=30 nM) for the glutamate site.
  20. GABA Receptor agonist

    Ru-32514 is an agonist of benzodiazepine receptor.
  21. CaM-KK inhibitor

    STO-609 is a selective and cell-permeable inhibitor of the Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively.
  22. amyloid P-IN-1 is used in the research of diseases or disorders wherein depletion of serum amyloid P component (SAP), including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
  23. NMDA antagonist

    UK-240455 is a potent and selective N-methyl D-aspartate (NMDA) glycine site antagonist.
  24. NMDA receptor agonist

    (-)-Aspartic acid is an endogenous NMDA receptor agonist.
  25. P2Y12 receptor inhibitor

    Clopidogrel thiolactone is a P2Y12 receptor inhibitor, is a potent antiplatelet agent.
  26. Piperazine Citrate is an organic compound that consists of a six-membered ring, containting two nitrogen atoms at opposite positions in the ring; first introduced in 1953 as an Anthelmintic.
  27. COMT inhibitor

    Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor.
  28. cholinesterase noncompetitive inhibitor

    (+)-Phenserine is a novel selective cholinesterase noncompetitive inhibitor with an IC50 of 45.3 μM.
  29. AChE inhibitor

    (±)-Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD).
  30. APP expression modulator

    ARN2966 is a potent post-transcriptional modulator of APP expression; reduces expression of APP with resultant lower production of Aβ.
  31. CaMKII inhibitor

    CaMKII-IN-1 is a potent and highly selective CaMKII inhibitor with IC50 of 63 nM.
  32. NMDA receptor antagonist

    Transcrocetinate disodium, extracted from saffron (Crocus sativus L.), acts as an NMDA receptor antagonist with high affinity.
  33. P2Y Receptor Inhibitor

    N6-(4-Hydroxybenzyl)adenosine is a inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.77-141 μM).
  34. Aldicarb sulfone(Temik sulfone) is a carbamate insecticide; is a cholinesterase inhibitor which prevents the breakdown of acetylcholine in the synapse.
  35. α7 nAChR agonist

    Nelonicline (ABT-126) is a selective neuronal nicotinic receptor agonist.
  36. GCS inhibitor

    Ibiglustat (Venglustat), a potential therapy for PD Parkinson??s disease, SRT in Fabry??s and Gaucher??s, is a selective, allosteric inhibitor of glucosylceramide synthase (GCS) with ability to cross the blood-brain barrier.
  37. Sigma-1 receptor agonist/muscarinic M1 agonist

    Blarcamesine, also known as AVex-73 and AE-37, is a muscarinic M1 agonist potentially for the treatment of Alzheimer's disease. It is an ς receptor ligand.
  38. mAChR modulator

    Rapacuronium bromide is an allosteric modulator of muscarinic acetylcholine receptor (mAChR).
  39. Aβ-aggregation inhibitor

    MDR-1339 (DWK-1339) is an orally active and blood-brain-barrier-permeable Aβ-aggregation inhibitor, used in the research of Alzheimer's disease.
  40. chemoprotective agent

    Methionine (MRX-1024; D-Methionine) is an effective chemoprotective agent which can also inhibit the neuronal activity through GABAA receptor activation.
  41. gamma secretase inhibitor

    BMS-906024 is an oral and selective gamma secretase inhibitor (GSI) that is a small molecule Notch inhibitor.
  42. P2X7 selective antagonist

    A 839977 is a P2X7 selective antagonist.
  43. GABAA receptor inverse agonist

    L-655708 is a potent α5 subunit-selective GABAA receptor inverse agonist (Ki = 0.45 nM).
  44. P2X7 receptor antagonist

    CE-224535 is a selective P2X7 receptor antagonist.
  45. NMDA receptor antagonist

    MDL 105519 is a potent and selective antagonist of glycine binding to the NMDA receptor.
  46. NMDA NR2B antagonist

    Radiprodil (RGH-896) is an orally active and selective NMDA NR2B antagonist. A potential therapeutic agent in treatment of neuropathic pain and possibly other chronic pain conditions.
  47. nAChR agnoist

    Monepantel is organic anthelmintic, and acts as a positive allosteric modulator of a nematode-specific clade of nicotinic acetylcholine receptor (nAChR) subunits.
  48. P2X7 allosteric modulator

    GW791343 3Hcl is a P2X7 allosteric modulator; exhibits species-specific activity and acts as a negative allosteric modulator of human P2X7 (pIC50 = 6.9 - 7.2).
  49. P2Y12 receptor inhibitor

    Clopidogrel is a well-known and orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
  50. γ-secretase inhibitor

    Compound E is a γ-secretase inhibitor.

Items 451-500 of 576

per page
Set Descending Direction